公开(公告)号：US20240200108A1

公开(公告)日：2024-06-20

申请号：US16500637

申请日：2018-04-05

申请人： POSTECH ACADEMY-INDUSTRY FOUNDATION ,  SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION

发明人： Gyoo Yeol Jung ,  Sang Woo Seo ,  Chae Won Kang ,  Hyun Gyu Lim

IPC分类号： C12P7/46 ,  C12N15/70 ,  C12P5/02

CPC分类号： C12P7/46 ,  C12N15/70 ,  C12P5/026 ,  C12N2800/101 ,  C12N2830/36 ,  C12N2840/10

摘要： The present invention relates to a gene expression cassette including a synthetic 5′ untranslated region (5′ UTR), a promoter, and a regulatory gene; a recombinant vector including a replication origin and the gene expression cassette; a recombinant microorganism which has the recombinant vector introduced thereinto and shows alleviated segregational instability and; a method for preparing a recombinant microorganism having alleviated segregational instability by introducing the recombinant vector thereinto; and a method for quantitatively controlling a plasmid copy number in a recombinant microorganism. According to the present invention, removal of infA and efp, which are genes indispensable for cells, encoding respectively for a translation initiation factor and a protein elongation factor (EF-P), from a microbial chromosome and introduction of the gene expression cassette including the regulatory gene with Escherichia coli serving as a host allow the stable maintenance of plasmids in an antibiotic-free medium without causing intercellular intrinsic variations. In addition, the precise control of expression levels of infA and efp in the recombinant microorganism by means of a promoter can lead to the quantitative control of PCN at high yield as well. Therefore, the present invention can find a broad spectrum of applications in a variety of industries producing recombinant proteins.

公开(公告)号：US20150296756A1

公开(公告)日：2015-10-22

申请号：US14532860

申请日：2014-11-04

申请人： Ann & Robert H. Lurie Children's Hospital of Chicago

发明人： Jhumku Kohtz

IPC分类号： A01K67/027 ,  C12N15/113

CPC分类号： A01K67/0276 ,  A01K2217/054 ,  A01K2217/056 ,  A01K2227/105 ,  A01K2267/0356 ,  C12N15/113 ,  C12N15/8509 ,  C12N2310/17 ,  C12N2830/36

摘要： The present invention relates to the field of neurological disorders and more particularly to the field of neuropsychiatric disorders. The invention provides non-human, transgenic animal models for brain disorders such as schizophrenia, bipolar disorders, compulsive disorders, addictive disorders and the like. The animals also have applications in the field of GABA neurotransmission and other disorders in which GABA-dependent gene regulation has a role.

摘要翻译： 本发明涉及神经障碍领域，更具体地涉及神经精神障碍领域。 本发明提供了用于诸如精神分裂症，双相情感障碍，强迫症，成瘾性疾病等脑疾病的非人类，转基因动物模型。 这些动物还在GABA神经传递领域和其中GABA依赖性基因调控具有作用的其他疾病领域中的应用。

公开(公告)号：US08884095B2

公开(公告)日：2014-11-11

申请号：US13383539

申请日：2010-07-17

申请人： Jhumku Kohtz

发明人： Jhumku Kohtz

IPC分类号： A61K49/00 ,  C12N15/85 ,  A01K67/00 ,  A01K67/027

CPC分类号： A01K67/0276 ,  A01K2217/054 ,  A01K2217/056 ,  A01K2227/105 ,  A01K2267/0356 ,  C12N15/113 ,  C12N15/8509 ,  C12N2310/17 ,  C12N2830/36

摘要： The present invention relates to the field of neurological disorders and more particularly to the field of neuropsychiatric disorders. The invention provides non-human, transgenic animal models for brain disorders such as schizophrenia, bipolar disorders, compulsive disorders, addictive disorders and the like. The animals also have applications in the field of GABA neurotransmission and other disorders in which GABA-dependent gene regulation has a role.

摘要翻译： 本发明涉及神经障碍领域，更具体地涉及神经精神障碍领域。 本发明提供了用于诸如精神分裂症，双相情感障碍，强迫症，成瘾性疾病等脑疾病的非人类，转基因动物模型。 这些动物还在GABA神经传递领域和其中GABA依赖性基因调控具有作用的其他疾病领域中的应用。

公开(公告)号：US20110250232A1

公开(公告)日：2011-10-13

申请号：US13150426

申请日：2011-06-01

申请人： Erich HOFFMANN

发明人： Erich HOFFMANN

IPC分类号： A61K39/145 ,  A61P31/16 ,  A61P31/14 ,  A61K39/12 ,  A61P37/04

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I-pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生系统的病毒产物。 该系统的一个应用是生产用作疫苗抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的优点是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 通过本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。

公开(公告)号：US07408053B1

公开(公告)日：2008-08-05

申请号：US08442750

申请日：1995-05-17

申请人： Paul A. Luciw ,  Dino Dina

发明人： Paul A. Luciw ,  Dino Dina

IPC分类号： C07H21/04

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K2319/00 ,  C12N9/0089 ,  C12N15/81 ,  C12N15/85 ,  C12N2740/16222 ,  C12N2800/108 ,  C12N2830/002 ,  C12N2830/15 ,  C12N2830/36 ,  C12N2830/55 ,  C12N2830/702 ,  C12Q1/703 ,  Y10S435/948 ,  Y10S435/974

摘要： Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

摘要翻译： 提供多核苷酸序列用于诊断与淋巴结病综合征和/或获得性免疫缺陷综合征相关的人宿主中的逆转录病毒感染的存在，用于表达多肽和使用多肽来制备抗体，其中多肽和抗体可以是 用作诊断试剂或用于治疗，例如疫苗和被动免疫。 这些序列提供与所指示的综合征相关的病毒感染因子的检测，并可用于表达抗原多肽。

公开(公告)号：US07312064B2

公开(公告)日：2007-12-25

申请号：US11093430

申请日：2005-03-29

申请人： Erich Hoffmann

发明人： Erich Hoffmann

IPC分类号： C12N7/00

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I-pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生系统的病毒产物。 该系统的一个应用是生产用作疫苗抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的优点是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 通过本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。

公开(公告)号：US07202085B2

公开(公告)日：2007-04-10

申请号：US11145451

申请日：2005-06-03

申请人： Tim N. Oulmassov ,  Kevin E. McBride ,  Paula C. Miller ,  John C. Anderson ,  Lyle D. Crossland ,  Thomas H. Adams ,  Barbara A. Qurollo ,  Victoria Gavrias

发明人： Tim N. Oulmassov ,  Kevin E. McBride ,  Paula C. Miller ,  John C. Anderson ,  Lyle D. Crossland ,  Thomas H. Adams ,  Barbara A. Qurollo ,  Victoria Gavrias

IPC分类号： C12N5/14 ,  C12N5/10 ,  A01H5/00

CPC分类号： C07D307/33 ,  A61K48/00 ,  C12N15/81 ,  C12N15/8214 ,  C12N15/8216 ,  C12N15/8217 ,  C12N15/8238 ,  C12N15/85 ,  C12N2830/00 ,  C12N2830/001 ,  C12N2830/002 ,  C12N2830/15 ,  C12N2830/30 ,  C12N2830/36 ,  C12N2840/105 ,  C12N2840/20 ,  C12N2840/203

摘要： DNA constructs and other compositions and methods for controlling gene expression in eukaryotic cells and organisms are derived from bacterial quorum sensing systems. One or more cis elements from the luxI promoter (“lux box”) or a functionally similar sequence are incorporated in a eukaryotic promoter. A receptor protein from the LuxR family of transcriptional regulators, upon binding an acylated homoserine lactone (AHL) compound, interacts with the lux box, modulating the activity of the promoter.

摘要翻译： 用于控制真核细胞和生物体中的基因表达的DNA构建体和其它组合物和方法源自细菌群体感测系统。 来自luxI启动子的一种或多种顺式元件（“lux框”）或功能上相似的序列并入真核启动子中。 来自转录调节物的LuxR家族的受体蛋白质在结合酰化的高丝氨酸内酯（AHL）化合物时，与lux框相互作用，调节启动子的活性。

公开(公告)号：US06620595B2

公开(公告)日：2003-09-16

申请号：US09855159

申请日：2001-05-14

申请人： Paula Marie Cannon ,  Maria Barcova

发明人： Paula Marie Cannon ,  Maria Barcova

IPC分类号： C12P2100

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2740/16043 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/30 ,  C12N2830/36 ,  C12N2830/60 ,  C12N2840/203

摘要： The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3′ LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.

公开(公告)号：US20020042136A1

公开(公告)日：2002-04-11

申请号：US09855159

申请日：2001-05-14

发明人： Paula Marie Cannon ,  Maria Barcova

IPC分类号： C12N015/867 ,  C12N007/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2740/16043 ,  C12N2830/00 ,  C12N2830/15 ,  C12N2830/30 ,  C12N2830/36 ,  C12N2830/60 ,  C12N2840/203

摘要： The invention provides novel retroviral vectors that have enhanced transcription termination structures. The termination structures comprise one or several heterologous upstream transcription termination enhancer (UE) sequences, or one or more additional copies of endogenous UE sequences operably associated with the 3null LTR polyadenylation signal. The retroviral vectors of the invention have various improved properties over conventional vectors, including stronger gene expression, enhanced vector titer and reduced interference with host cell gene expression resulting from read-through of vector initiated transcriptional events.

摘要翻译： 本发明提供具有增强的转录终止结构的新型逆转录病毒载体。 终止结构包含一个或几个异源上游转录终止增强子（UE）序列，或与3'LTR多聚腺苷酸化信号可操作地相关的内源性UE序列的一个或多个附加拷贝。 本发明的逆转录病毒载体与常规载体相比具有各种改进的性质，包括更强的基因表达，增强的载体滴度和降低的通过载体启动的转录事件的读取导致的宿主细胞基因表达的干扰。

公开(公告)号：US5763270A

公开(公告)日：1998-06-09

申请号：US484723

申请日：1995-06-07

申请人： Eric M. Eastman ,  Ross H. Durland

发明人： Eric M. Eastman ,  Ross H. Durland

IPC分类号： C12N15/09 ,  A61K48/00 ,  C12N15/70 ,  C12N15/85 ,  C12N15/63 ,  A61K35/00 ,  C12Q1/68

CPC分类号： C12N15/85 ,  C12N15/70 ,  A61K48/00 ,  C12N2800/30 ,  C12N2820/002 ,  C12N2820/55 ,  C12N2830/002 ,  C12N2830/006 ,  C12N2830/36 ,  C12N2830/55 ,  C12N2840/20

摘要： This invention relates to plasmid constructs useful for nonviral human gene therapy. The plasmid constructs incorporate plasmid elements for achieving high copy number, avoiding plasmid instability an providing a plasmid selection process. These constructs can be used to deliver nucleic acids to cells in vehicles which are compatible with human therapeutic use.